Compare · MPLN vs NOVS
MPLN vs NOVS
Side-by-side comparison of MultiPlan Corporation (MPLN) and Novus Capital Corporation (NOVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- MPLN operates in Consumer Discretionary, while NOVS operates in Finance - the two are in different parts of the market.
- MPLN carries a market cap of $2.41B.
- MPLN has more recent analyst coverage (7 ratings vs 0 for NOVS).
- Company
- MultiPlan Corporation
- Novus Capital Corporation
- Price
- $23.17-1.43%
- -
- Market cap
- $2.41B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Business Services
- Business Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 0
- 0
- Recent ratings
- 7
- 0
MultiPlan Corporation
MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services, which reduce medical costs through data-driven algorithms that detect claims over-charges and recommend or negotiate reimbursement; network-based services that reduce medical costs through contracted discounts with healthcare providers; and payment integrity services, which reduce medical costs by identifying and removing improper and unnecessary charges paid during the claim. It also provides health benefit plans, which features reference-based pricing and tools to engage health plan members and providers to make the use of benefits before and after care delivery. The company serves national insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, third party administrators, insurance bill review companies, Taft-Hartley plans, and other entities that pay medical bills in the commercial healthcare, government, workers' compensation, and auto medical markets. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.
Latest MPLN
- ClearNote Health's Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev's National PPO Networks
- SEC Form 10-K filed by MultiPlan Corporation
- MultiPlan Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025
- MultiPlan Corporation filed SEC Form 8-K: Other Events
- Claritev Provides Oracle Cloud HCM Customers with Actionable Insights for Healthcare Cost Optimization and Plan Design
- MultiPlan Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- MultiPlan Enters New Era and Unveils New Brand, Claritev, Reflecting Company's Transformation and Mission to Support the Healthcare Continuum
- Amendment: SEC Form SCHEDULE 13G/A filed by MultiPlan Corporation
- MultiPlan Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
Latest NOVS
- SEC Form 4: J Robert Laikin sold $3,768,538 worth of Common Stock (162,500 units at $23.19), decreasing direct ownership by 37% to 276,635 units
- SEC Form SC 13G filed
- SEC Form EFFECT filed
- SEC Form 424B3 filed
- SEC Form S-1/A filed
- SEC Form 8-K filed
- SEC Form 8-K/A filed
- SEC Form 8-K filed
- SEC Form SC 13G filed
- SEC Form SC 13G/A filed